PTO/SB/17i (04-05)
Approved for use through 7/31/2007. OMB 651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number.

## PROCESSING FEE **Under 37 CFR 1.17(i) TRANSMITTAL**

(Fees are subject to annual revision)

Send completed form to: Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

09/589,288-Conf. #1519 **Application Number** June 8, 2000 **Filing Date** Guo-Liang Yu **First Named Inventor** 1647 Art Unit B. E. Bunner **Examiner Name** PF343P3C5 Attorney Docket Number

Enclosed is a paper filed under 37 CFR  Payment of \$ 130.00 is enclosed.  This form should be included with the above montioned page.	
This form should be included with the above-mentioned paper and faxed or mailed to the Office using the appropriate Mail Stop, if applicable. For transmittal of petition fees under 37 CFR 1.17(f), (g) or (h), see form PTO/SB/17p.	
Payment of Fees (small entity amounts are NOT available for the processing fees)	
The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 08-3425 :  x processing fee under 37 CFR 1.17(i) x any deficiency of fees and credit of any overpayments	
Enclose a duplicative copy of this form for fee processing.	
Check in the amount of \$	_ is enclosed.
Payment by credit card (Form PTO-2038 or equivalent enclosed). Do not provide credit card information on this form.	
Processing Fees under 37 CFR 1.17(i): Fee \$130	Fee Code 1808 for all,
	Except for §1.221 papers (Fee Code 1803)
For papers filed under:	
§ 1.28(c)(3) – for processing a non-itemized fee deficiency based on an error in small entity status.  § 1.41 – for supplying the name or names of the inventor or inventors after the filing date without an oath or declaration as prescribed by §1.63, except in provisional applications.  § 1.48 – for correcting inventorship, except in provisional applications.  § 1.52(d) – for processing a nonprovisional application filed with a specification in a language other than English.  § 1.53(b)(3) – to convert a provisional application filed under § 1.53(c) into a nonprovisional application under §1.53(b).  § 1.55 – for entry of late priority papers.  § 1.71(g)(2) – to enter an amendment to the specification for purposes of 35 U.S.C. 103(c)(2) if not filed within the cited time periods § 1.99(e) – for processing a belated submission under § 1.99.  § 1.103(b) – for requesting limited suspension of action, continued prosecution application (§ 1.53(d)).  § 1.103(d) – for requesting limited suspension of action, request for continued examination (§ 1.114).  § 1.103(d) – for requesting deferred examination of an application.  § 1.217 – for processing a redacted copy of a paper submitted in the file of an application in which a redacted copy was submitted for the patent application publication.  § 1.221 – for requesting voluntary publication or republication of an application. Fee Code 1803  § 1.291(c)(5) – for processing a second or subsequent protest by the same real party in interest.  § 1.497(d) – for filing an oath or declaration pursuant to 35 U.S.C. 371(c)(4) naming an inventive entity different from the inventive entity set forth in the international stage.  § 3.81 – for a patent to issue to assignee, assignment submitted after payment of the issue fee.	
_ Wille Shanno	May 5, 2006
Signature	Date
Michele Shannon	47,075
Typed or printed name	Registration No., if applicable



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Docket No.: PF343P3C5

Yu et al.

Application No.: 09/589,288

Confirmation No.: 1519

Filed: June 8, 2000

Art Unit: 1647

For: Methods of Treatment Using Antibodies to

Examiner: B. E. Bunner

Neutrokine-alpha (As Amended)

## AMENDMENT AND REQUEST FOR INTERFERENCE

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants request that the following amendments and remarks be entered into the above-identified application. Applicants submit concurrently herewith a Return Receipt Card and a Processing Fee Transmittal Sheet, as well as the following items:

- (a) Appendix A-Copy of U.S. Patent No. 6,869,605;
- (b) Appendix B- Proposed Count;
- (c) Appendix C- Claims of U.S. Patent No. 6,869,605 Corresponding to the Proposed Count;
- (d) Appendix D- Claims of the Present Application Corresponding to the Proposed Count;
- (e) Appendix E- Comparison of Claim 1 of U.S. Patent No. 6,869,605 With Claims 195 and 196 of the Present Application;
- (f) Appendix F- Priority Claim for U.S. Patent No. 6,869,605;
- (g) Appendix G- Priority Claim for the Present Application;
- (h) Appendix H- Support for the Claims of the Present Application in the Disclosure of the Present Application;
- (i) Appendix I- Constructive Reduction to Practice;
- (j) Appendix J- Declaration of Amy Orr (with attached Exhibits A-C);
- (k) Appendix K- Declaration of David Hilbert (with attached Exhibit A);

- (l) Appendix L- Copy of Amendment dated January 16, 2004 filed by Biogen during the prosecution of U.S. Patent No. 6,869,605 and copies of the Wendy *et al.* and Furie *et al.* 2003 American College of Rheumatology Abstracts;
- (m) Appendix M- Janeway, C. & P. Travers. *Immunobiology: The Immune System in Health and Disease*, (Current Biology Ltd./Garland Publishing, London) 1994.
   pp. 1:8, 3:5, 3:38 and 8:2;
- (n) Appendix N- Abbas, A.K. et al., Cellular and Molecular Immunology, (W.B. Saunders Company, Harcourt Brace Jovanovich, Inc., Philadelphia) 1991. pp. 187 and 189;
- (o) Appendix O- Comparison of the Amino Acid Sequence of the Proposed Count With SEQ ID NO:1 from U.S. Patent No. 6,869,605 (Biogen) and SEQ ID NO:2 from the Present Application (HGS);
- (p) Appendix P- Winter, F. and C. Milstein (1991) Nature 349:293-299;
- (q) Appendix Q- Antibodies, A Laboratory Manual ed. by Harlow and Lane (Cold Spring Harbor Press: (1988) p. 115;
- (r) Appendix R- Golub, E.S. and D.R. Green, *Immunology: A Synthesis* (Sinauer Associates, Inc. Sunderland, MA) 1991. p. 134;
- (s) Appendix S- Otten et al., (1989) Proceedings of the National Academy of Sciences, USA 86:10059-10063; and
- (t) Appendix T- Waldmann, TA, (2003) Nature Medicine 9:269-277.

Amendments to the Claims begin on page 3.

Remarks begin on page 5.